Return to study ST001047 main page
MB Sample ID: SA070542
| Local Sample ID: | sample_63 |
| Subject ID: | SU001087 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU001087 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| sample_63 | SA070542 | FL011183 | Sample | Sample_Type |
Collection:
| Collection ID: | CO001081 |
| Collection Summary: | Midstream urine samples were collected from 43 GC, 40 BN, and 40 HE patients from January 2009 to December 2014 from three hospitals in Edmonton, Canada. GC samples were collected prior to chemoradiotherapy and surgery. All patients provided written informed consent. Ethics approval was obtained from the Health Research Ethics Board at the University of Alberta. Inclusion criteria for cancer patients were: biopsy-confirmed diagnosis of GC, age >=18 years, and no metastases on their staging computed tomography scans. BN patients had to experience gastrointestinal symptoms (such as haematemesis or epigastric discomfort) and must have endoscopic evidence within the past 6 months of consent that symptoms were not due to a malignant cause. BN patients had the following conditions: gastritis, gastro- oesophageal reflux disease (GORD), portal hypertensive gastro- pathy, varices, gastritis, ulcers, and polyps. HE controls had no declared history of cancer and no gastrointestinal symptoms. Groups were matched on age, gender, and BMI. Exclusion criteria included: breastfeeding, pregnancy, significant cardiac disease with New York Heart Association XClass II, systemic infection, prior cancer, and glomerular filtration rate 30 ml min ^-1. |
| Sample Type: | Urine |
Treatment:
| Treatment ID: | TR001101 |
| Treatment Summary: | Within 2h of collection, one ml aliquots of urine mixed with 50ml of 0.42% sodium azide preservative were prepared and biobanked at -80 °C. |
Sample Preparation:
| Sampleprep ID: | SP001094 |
| Sampleprep Summary: | Urine aliquots were thawed and prepared by adding 75 μL of a chemical shift standard (Chenomx Inc., Edmonton, Alberta, Canada) containing 4.6 mM 2,2-dimethyl-2-silapentane-5-sulfonate-d6 sodium salt (DSS-D6), 0.20% w/v NaN3 and 98.0% v/v D2O, to 675 μL of urine. Samples were titrated to a final pH of 6.75 ± 0.05 using small volumes of sodium hydroxide (NaOH) and hydrochloric acid (HCl). Samples were centrifuged for 10 minutes at 10000 x g at 4 °C to remove particulate matter. Next, 700 μL of supernatant was transferred to a 4” long, 5 mm diameter NMR tube (Wilmad, Nuena, NJ, USA 505-PS-4) immediately prior to NMR acquisition. |
Analysis:
| MB Sample ID: | SA070542 |
| Analysis ID: | AN001711 |
| Analysis Type: | NMR |
| Num Factors: | 2 |
| Num Metabolites: | 129 |
| Units: | area |
NMR:
| NMR ID: | NM000127 |
| Analysis ID: | AN001711 |
| Instrument Name: | 600 MHz Varian Inova spectrometer |
| Instrument Type: | FT-NMR |
| NMR Experiment Type: | 1D 1H |
| Spectrometer Frequency: | 600 MHz |
